Eosinophils as a Biomarker in Asthma and COPD
| Autor: | Jose Carlos Herrera Garcia |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
COPD
business.industry InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL respiratory system medicine.disease respiratory tract diseases 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Immunology Biomarker (medicine) Medicine 030212 general & internal medicine business GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) Asthma |
| DOI: | 10.5772/intechopen.94240 |
| Popis: | Asthma and COPD are two diseases related to eosinophils. But at present, we do not know with certainty how much these cells participate in these diseases, beyond that the treatment of the underlying cause produces the resolution of eosinophilia in a “reactive” way. Eosinophil-related diseases are a spectrum of systemic diseases such as Asthma and COPD in pneumology area. Under inflammatory conditions, the number of circulating eosinophils or tissues can increase dramatically, with rapid development of eosinophilia and we can obtain in a simple laboratory test. In general, the number of eosinophils in the blood can provide useful information and considering the differential diagnosis and for the subsequent test of patients presenting with eosinophilia. The treatment of eosinophilia currently in number of 300 cells in which is the criteria and the target to be treat. The best known and most used of all treatments for diseases related to eosinophils are corticosteroids, which decrease circulating and tissue eosinophils in a few hours, through mechanisms that include the direct activation of eosinophil program death. Targeted treatment against eosinophils could improve airway remodeling through mechanisms that are not fully known, and their effects on lung function are variable and decreasing symptoms in patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|